Rapid advances in artificial intelligence over the last decade have the potential to revolutionize how drugs are developed. These are the top 10 companies in Europe that are working to make AI drug discovery a reality.
Drug development is a slow and increasingly expensive process. Artificial intelligence (AI) has the potential to make the drug development process quicker, cheaper and more efficient. This technology can make scanning vast libraries of chemical compounds that might be able to treat a certain disease easier, can speed up the analysis of biomedical information from the literature, and can help companies recruit the most suitable patients for clinical trials. AI can also streamline the design of better drugs and incorporate new data, such as genomic analysis, to help personalized medicine become a reality.
There are now an increasing number of companies that are using AI to improve drug discovery and development in a variety of different ways. We enlisted the help of experts in the industry to select the top European companies in this area. As ever, these are in no particular order.
Location: Oxford, UKFounded: 2012
Exscientia was one of the first companies to apply AI technology to drug discovery. Its focus is to quickly identify and optimize drug candidates that are more likely to succeed in clinical trials than those selected by conventional means.
The companys first AI-designed drug candidate, to treat obsessive-compulsive disorder, began human testing in a phase I trial earlier this year. It took Exscientia 12 months to bring the candidate to clinical trials rather than the average time of around five years. More recently, the company announced it was working with US partners to apply its technology to searching for drug candidates to treat Covid-19.
The Oxford-based company has deals with Bayer, BMS, Sanofi, GSK, and Celgene to co-develop new drugs for a variety of diseases and conditions. Exscientia also closed an impressive 54M Series C round at the end of April, in the midst of the Covid-19 pandemic.
Location: Cambridge, UKFounded: 2014
Healx uses AI to analyze extensive medical research data with the goal of repurposing and finding new combinations of existing drugs to treat rare diseases such as fragile X syndrome, Angelman syndrome and muscular dystrophy.
The company raised a 50.8M Series B round in October 2019. Shortly after, Healx announced it was committing 17M to run its Rare Treatment Accelerator program, allowing patient groups a chance to work with the company to find new treatments for rare diseases.
The companys most advanced program, a drug repurposed for fragile X syndrome, took less than two years to reach clinical trials instead of the normal five-to-seven years this process usually takes. Like many others, Healx is using its technology to search for treatments for Covid-19.
Location: London, UKFounded: 2013
BenevolentAI has developed an AI platform that can identify new drug target candidates for any therapeutic area. The company has its own pharmaceutical team to investigate potential leads and develop their own products. The company began life as Stratified Medicine before changing its name in 2016.
BenevolentAI is working in a variety of disease areas including Alzheimers and ALS. While the company is working on its own drug candidates, it also has various partnerships including with the big pharma companies AstraZeneca and Novartis. BenevolentAI recently hit the news when it discovered a potential treatment for Covid-19, the existing rheumatoid arthritis drug baricitinib, which has shown to improve and speed up the recovery of hospitalized patients with Covid-19.
The company technically reached unicorn status in 2018 when it achieved a valuation of 1.7B after a big fundraising. However, the companys valuation suffered significantly when Neil Woodford, who had been a major investor, was forced to wind up his fund in 2019, though the valuation has since improved again.
Location: Eschborn, GermanyFounded: 2011
Unlike other companies in the field, Innoplexus doesnt develop its own pharmaceuticals, Instead, the firm gives pharma companies, biotechs, contract research organizations and life sciences professionals access to its data platform to help them design better drugs and improve decision making throughout the drug development process.
The company uses AI and blockchain to search published papers, online data from presentations, symposiums and conferences, clinical trial data, and publicly available hospital data as well as unpublished datasets.
Last spring, Innoplexus closed a Series C round worth an undisclosed amount in the double-digit millions. In March, The company released an analysis of hundreds of clinical studies that suggested a treatment for Covid-19 consisting of hydroxychloroquine combined with a variety of other drugs, including Gileads antiviral remdesivir.
Location: Copenhagen, DenmarkFounded: 2008
Evaxion has a focus on infectious diseases and oncology. The company has developed two AI platforms that can be used to create immunotherapies by selecting the antigens that are most likely to produce strong immune responses against infections or cancer.
One of the platforms is used for the development of personalized cancer immunotherapies. In April 2019, the company dosed its first patient with its lead candidate, a therapeutic vaccine targeting solid tumors. The other platform can identify vaccine antigens that trigger protective responses against pathogenic bacteria in less than a day.
At the end of last year the company raised 16M. As with most of the other companies in this space, Evaxion has launched its own Covid-19 effort an AI platform designed to enable a faster response to emerging viral pandemics by identifying potential vaccines and taking them to clinical trials within just 13 weeks.
Location: Frankfurt am Main, GermanyFounded: 2016
Genome Biologics has a focus on RNA interference therapies for cardiovascular and cardiometabolic diseases. The company uses an AI platform to assist in identifying suitable drug targets and also allows 2D and 3D investigation of RNAi disease targets in a variety of animal models.
Genome Biologics was developed with support from the Johnson & Johnson Innovation Labs Incubator in Beerse, Belgium, where the company has an office. The company is still young, but has raised 2.5M in grant and seed funding to further develop its technology. Its lead candidate treatment is expected to start phase I/II testing in heart failure patients next year.
Genome Biologics recently joined Blue Knight, a collaboration of companies created by Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) in the US, that aims to anticipate potential global health threats and infectious diseases.
Location: Lyon, FranceFounded: 2010
Novadiscovery uses data from preclinical and clinical studies to model a drugs effect on patients and predict whether it will be successful or not at treating a specific disease. The company has worked on a wide range of indications including liver disease, respiratory disease, hepatitis, immuno-oncology, and cardiovascular disease.
Compared to other similar companies, Novadiscovery is able to work with small and large data sets alike. The AI platform is also designed to be transparent and allow users to check if the tool is working correctly.
The company raised 5M in Series A funding earlier this year to develop its technology further and offer it to clients as a cloud-based service where users pay for access.
Location: Dublin, IrelandFounded: 2014
Nuritas uses its AI platform to search and analyze large libraries to find potential drug candidates or nutritional additives. In particular, the company focuses on identifying and developing peptide drugs.
Although it has a strong focus on developing nutritional supplements, Nuritas is also using its platform to develop potential drug candidates. The company is currently investigating a fibrosis target that is implicated in a number of diseases including liver, renal and cardiac disease.
Nuritas has raised 53.9M since it was founded in 2014 and has collaborations with big players such as Nestle, Johnson & Johnson and BASF. The company has also joined the Covid-19 effort and is searching for antiviral peptides that could block the virus causing Covid-19, SARS-CoV-2, from infecting cells or locally reduce lung inflammation without the need for complete immunosuppression.
Location: Budapest, HungaryFounded: 2015
Turbine has a focus on cancer. The company has built a dynamic computational model of human cell biology that uses AI to predict how cancer cells respond to drugs and finds new targets, biomarkers and therapies. By running thousands of simulated experiments, this technology can dramatically speed up drug development.
Turbine is currently focusing on DNA damage repair targets, found in 30% of cancers, particularly in patients resistant to other therapies. The company secured 3M in seed funding at the end of last year and has partnered with German big pharma Bayer to develop new applications for its existing cancer drugs. It also has its own preclinical-stage drug development programs in development.
Location: Tel Aviv, IsraelFounded: 2016
Tel Aviv-based CytoReason is definitely worth a mention on this list. The company has one of the largest libraries of human molecular data in the world. It uses this information to create computational cell models of the human immune system to advance drug development.
For example, an analysis of melanoma biopsies using the companys AI platform identified that patients who responded to the drug nivolumab had higher numbers of adipocyte cells than those who did not. The company has also discovered several potential new targets for this cancer that had not previously been investigated.
CytoReason has not revealed its funding to date, but has high-value partnerships with several big pharma companies including Pfizer, GSK and Roche focusing on drug development in immunology.
Visit link:
Top 10 Companies Combining AI and Drug Discovery in... - Labiotech.eu
- Oncology Precision Medicine Market Research, Industry Trends and Global Forecasts, 2035 - Rising Partnership and ... - PR Newswire - March 18th, 2024
- 3 Precision Medicine Stocks That Could Benefit From the Industry's Rise - InvestorPlace - March 18th, 2024
- Prime Editing Approach Provides a Faster, More Effective Way to Screen for Cancer Mutations - Inside Precision Medicine - March 18th, 2024
- Global Genomics Industry Research 2024-2031: Rising Adoption of Personalized Medicines and Gene Therapies ... - PR Newswire - March 18th, 2024
- CAR T-Cell Therapy Successfully Used to Treat Brain Tumors - Inside Precision Medicine - March 18th, 2024
- Revolutionizing Wellness: The Power of Personalised Health Tech - AutoGPT - March 18th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- AI and predictive medicine: Recent advances - News-Medical.Net - March 10th, 2024
- Personalized medicine is coming, but who will have access to it? - AAMC - March 10th, 2024
- Why personalized medicine is a business trend to watch in 2024 - HealthLeaders Media - March 10th, 2024
- AI helps cardiologists deliver personalized healthcarebut there is still plenty of work to do - Cardiovascular Business - March 10th, 2024
- Q&A: How AI and wearable technologies are transforming medicine - EMS1.com - March 10th, 2024
- HealthTech Revolution: Wearables, AI, and the Personalized Future of Healthcare - GearBrain - March 10th, 2024
- Redefining Healthcare: The Rise of Personalized Medicine and the Shift from Conventional Care - Medriva - March 10th, 2024
- Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer - OncLive - March 10th, 2024
- Chemotherapy Plus High Doses of Radiation Effective for Treating Non-Small Cell Lung Cancer - Inside Precision Medicine - January 17th, 2024
- It's Time to Fully Embrace Precision Medicine's Promise in Pediatrics - Healthcare Innovation - January 17th, 2024
- Special Report: Radiation Oncology Takeaways from RSNA23 - Imaging Technology News - January 17th, 2024
- Advanced Therapeutics Pharmaceutical Outsourcing Market to Surge at a CAGR of 4.4% by 2034 Amid Growing ... - PR Newswire - January 17th, 2024
- Simulations of the human body and advanced data promise more personalized medical treatment - Medical Xpress - January 17th, 2024
- United States Single Cell Genomics and Proteomics Growth Opportunities: The Integration of Multi-Omics Data to Drive ... - PR Newswire - January 17th, 2024
- Advances Usher In Era of Personalized Treatment for Obesity - Gastroenterology & Endoscopy News - January 17th, 2024
- Unveiling the Reality of Personalized Medicine: Yale Study Highlights Limitations in Current Predictive Models - Medriva - January 17th, 2024
- Digital Twins: The Future of Personalized Healthcare - BNN Breaking - January 17th, 2024
- Healthcare in 2024: A Vision of the Future | Future of Healthcare Predictions - Medriva - January 17th, 2024
- Utilization of the microbiome in personalized medicine - Nature.com - December 22nd, 2023
- Focusing on Women's Health - Inside Precision Medicine - December 22nd, 2023
- Revolutionizing Healthcare: Innovations in Regenerative Medicine Offer Hope - Inside Precision Medicine - December 22nd, 2023
- AI in Genomics Market Predicted to Grow at CAGR of 40.6% by 2031, with Revenue $9.8 Billion - PharmiWeb.com - December 22nd, 2023
- Innovative Technologies Transforming Cancer Treatment - BNN Breaking - December 22nd, 2023
- Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com - December 22nd, 2023
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022